The Open Immunology Journal


ISSN: 1874-2262 ― Volume 7, 2014

In Vivo Administration of a PKA Type I Inhibitor (Rp-8-Br-cAMPS) Restores T-Cell Responses in Retrovirus-Infected Mice

The Open Immunology Journal, 2008, 1: 20-24

Btissam Nayjib, Mustapha Zeddou, Pierre Drion, Jacques Boniver, Kjetil Tasken, Souad Rahmouni, Michel Moutschen

Immunology and Infectious Diseases Laboratory, GIGA-Research, B34, University of Liège-CHU Liège, 4000 Liège, Belgium.

Electronic publication date 15/4/2008
[DOI: 10.2174/1874226200801010020]


Murine AIDS (MAIDS) is caused by infection with the murine leukemia retrovirus RadLV-Rs and is characterized by T-cell anergy and severe immunodeficiency with increased susceptibilty to several experimental opportunistic infections as observed in HIV infection. T cell anergy is associated with an increase of intracellular cAMP level, triggering a multistep pathway involving activation of PKA type I and resulting in inhibition of proximal TCR signaling. We have previously demonstrated that blocking PKA type I using the selective inhibitor Rp-8-Br-cAMPS, restores T-cell function in vitro in MAIDS as well as in HIV infection. In the present report, we investigated the effect of parenteral administration of Rp-8-Br-cAMPS in mice with MAIDS. We show that the compound is not toxic and partially restores the ex vivo proliferative responses to anti-CD3 mAb, but that it has no effect on the lymphadenopathy and splenomegaly characterizing the MAIDS syndrome.

Download PDF

Browse Contents

Webmaster Contact:
Copyright © 2015 Bentham Open